Short Incubation Methylaminolevulinate Photodynamic Therapy Without Occlusion

PHASE3CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 31, 2009

Primary Completion Date

December 31, 2010

Study Completion Date

January 31, 2011

Conditions
Actinic Keratosis
Interventions
DRUG

Methylaminolevulinate (Metvix, Metvixia)

2-4 g of cream applied to entire face at Day 0 for 90 minutes without occlusion prior to light treatment. If any actinic keratoses remained after 4 weeks the treatment was repeated at Week 4.

DEVICE

Photodynamic Therapy (Aktilite)

Device set to 37 J/cm². Red light wavelength is approximately 630 nm.

Trial Locations (1)

H2K 4L5

Innovaderm Research Inc, Montreal

Sponsors
All Listed Sponsors
collaborator

Galderma Canada

OTHER

lead

Innovaderm Research Inc.

OTHER

NCT00926952 - Short Incubation Methylaminolevulinate Photodynamic Therapy Without Occlusion | Biotech Hunter | Biotech Hunter